Abstract: Provided are a novel compound that effectively antagonizes P2X3 receptor, a preparation method thereof, and use thereof in the preparation of drugs. The compound is a compound represented by Formula I, or a tautomer, a stereoisomer, a hydrate, a solvate, a pharmaceutically acceptable salt, or a prodrug thereof.

Abstract: The present disclosure provides a novel compound effective in antagonizing EP4, which is a compound represented by Formula I, or a tautomer, stereoisomer, hydrate, solvate, pharmaceutically acceptable salt or prodrug of the compound represented by Formula I: wherein: R1 is selected from —CH3, —CHF2, and —CF3; R2 is selected from C2-C6 alkyl, C3-C6 cycloalkyl, C2-C6 halogen-substituted alkyl, C3-C6 halogen-substituted cycloalkyl; R3 is selected from hydrogen, halogen, C1-C2 alkyl, C1-C2 fluorine- or chlorine-substituted alkyl; R4 is selected from hydrogen, halogen, C1-C6 alkyl, C1-C6 alkoxyl, C1-C6 halogen-substituted alkyl, C1-C6 halogen-substituted alkoxyl.

Abstract: The present disclosure relates to pyrimidine compounds, and more specifically, relates to pyrimidine compounds, preparation methods thereof, and uses thereof in manufacture of medicaments. Provided is a compound represented by Formula (I) or a tautomer, stereoisomer, hydrate, solvate, pharmaceutical acceptable salt, or prodrug of the compound represented by Formula (I). The compound has a significant inhibitory effect on ATX enzyme, exhibits excellent liver metabolism stability, is metabolized more slowly in the human body, and has higher exposure.

Abstract: Provided is a new compound capable of effectively inhibiting ATX. The compound is represented by formula I, or the compound is a tautomer, a stereoisomer, a hydrate, a solvate, a salt, or a prodrug of the compound represented by formula I. In formula (I), R1 and R2 are independently selected from —H or —CH3, provided that: R1 and R2 are not —H at the same time or are not —CH3 at the same time.